Rhenium-188 as an alternative to Iodine-131 for treatment of prostate cancer following tissue-specific sodium iodide symporter gene transfer

Willhauck, Michael J.; Samani, Bibi Rana Sharif; Wolf, Ingo; Gildehaus, Franz-Josef; Finke, Mark D.; Göke, B.; Senekowitsch–Schmidtke, Reingard; Morris, Jonathan C.; Spitzweg, Christine

doi:10.1055/s-2007-972422

Exp Clin Endocrinol Diabetes

2007

DOI: 10.1055/s-2007-972422

|View full text |Cite

Rhenium-188 as an alternative to Iodine-131 for treatment of prostate cancer following tissue-specific sodium iodide symporter gene transfer

Michael J. Willhauck¹,

Bibi Rana Sharif Samani²,

Ingo Wolf³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy

Xia

Wang

et al. 2016

Cancer Gene Ther

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Currently, the clinical strategies available for the treatment of HCC remain insufficient for the poor prognosis. Sodium/iodide symporter (NIS)-based radioiodine therapy is proposed as a promising therapeutic strategy for the treatment of HCC. However, it is difficult for HCC cells to trap iodine for the lower expression of NIS. Small activating RNA (saRNA) is a newly identified small double-stranded RNA (dsRNA) that can induce endogenous gene expression by targeting promoter sequences. Here, we designed an saRNA (saRNA-482) that targeted the NIS promoter sequences. In the cultured HepG2 cells and Hep3B cells, the expressions of NIS were upregulated after transfection of saRNA-482. In addition, the uptake ofI increased in the cultured HepG2 and Hep3B cells transfected with saRNA-482. Furthermore, the cell viabilities were significantly inhibited in the saRNA-482-transfected HepG2 and Hep3B cells after I treatment. Meanwhile, the apoptosis of saRNA-482-transfected HepG2 and Hep3B cells significantly increased afterI treatment. The results suggest that RNA activation-mediated upregulation of NIS may have an endoradiotherapeutic potential in the treatment of HCC.

show abstract

Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy

Xia

Wang

et al. 2016

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Rhenium-188 as an alternative to Iodine-131 for treatment of prostate cancer following tissue-specific sodium iodide symporter gene transfer

Cited by 1 publication

References 0 publications

Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy

Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy

Contact Info

Product

Resources

About